Bone marrow steady-state CD34+/CD71- cell content is a predictive value of rG-CSF-mobilized CD34+ cells.
Thirty-four patients diagnosed with breast cancer were included in a prospective study evaluating the bone marrow (BM) CD34+/CD71- cell content, as a predictive parameter of the CD34+ cell mobilization after rG-CSF administration. Analysis of the concentration of medullary CD34+/CD71- cells before priming schedules was significantly related with the collection of CD34+ cells in apheresis day 1 (P = 0.03, r = 0.36), apheresis day 1 + day 2 (P = 0.01, r = 0.42) or the total CD34+ cells collected (P = 0.005, r = 0.47). A BM CD34+/CD71- cell concentration greater than or less than a cut-off value of 30/microl was significantly associated with the yield of CD34+ cells collected by cytapheresis procedures (mean values 3.12 x 10(6)/kg, and 2.19 x 10(6)/kg, respectively, P = 0.013). These results suggest that in breast cancer patients undergoing priming with rG-CSF, steady-state BM CD34+/CD71- measurement is a relevant predictive parameter of CD34+ mobilization.
Osma
M M
MM
Unit of Hematology and Hemotherapy, School of Medicine, Hospital General Universitario, Murcia, Spain.
Ortuño
F
F
de Arriba
F
F
Lozano
M L
ML
Heras
I
I
Moraleda
J M
JM
Vicente
V
V
D000328:Adult; D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34 / Q000032:analysis*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis*; D001781:Blood Component Removal; D001854:Bone Marrow Cells / Q000187:drug effects*; D002452:Cell Count; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011990:Receptors, Transferrin; D011994:Recombinant Proteins
D015703:Antigens, CD; D018952:Antigens, CD34; D000944:Antigens, Differentiation, B-Lymphocyte; C068126:CD71 antigen; D011990:Receptors, Transferrin; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor